Coronavirus Pandemic

Clinical characteristics and outcomes of COVID-19: Experience at a major tertiary care center in Pakistan

Nosheen Nasir¹, Kiren Habib¹, Iffat Khanum¹, Naveera Khan¹, Zehra A Muhammad², Syed Faisal Mahmood¹

¹ Section of Infectious Diseases, Department of Medicine, Aga Khan University, Karachi, Pakistan
² Department of Surgery, Aga Khan University, Karachi, Pakistan

Abstract

Introduction: Limited data exist on clinical characteristics and outcomes of hospitalized COVID-19 patients in low-middle income countries. We aimed to describe the clinical spectrum and outcomes of hospitalized COVID-19 patients at a tertiary-care center in Karachi, Pakistan.

Methodology: We conducted an observational study of adult COVID-19 patients hospitalized between February-June 2020. Patients with a discharge diagnosis of COVID-19 and PCR positivity were included. We created logistic regression models to understand association of clinical characteristics with illness severity and in-hospital mortality.

Results: The study population comprised 445 patients [67% males, median age 53 (IQR 40-64) years]. Majority of patients (N = 268; 60%) had ≥ 1 co-morbidity [37.5% hypertension, 36.4% diabetes]. In-hospital mortality was 13%. Age ≥ 60 (aOR =1.92; 95% CI = 1.23-3.03), shortness of breath (aOR=4.43; 95% CI=2.73-7.22), CRP ≥150mg/L (aOR:1.77; 95% CI=1.09-2.85), LDH ≥ 500 IU/L (aOR:1.98; 95% CI=1.25-3.16), Neutrophil-Lymphocyte ratio (NLR) ≥5 (aOR:2.80; 95% CI = 1.77-4.42) and increase in serum creatinine (aOR:1.32; 95%CI=1.07-1.61) were independently associated with disease severity. Septic shock (aOR: 13.27; 95% CI=3.78-46.65), age ≥ 60 (aOR: 3.26; 95% CI=1.07-9.89), Ferritin ≥ 1500ng/ml (aOR: 3.78; 95% CI=1.21-11.8), NLR ≥ 5 (aOR: 4.04; 95% CI=1.14-14.35) and acute kidney injury (aOR: 5.52; 95% CI=1.78-17.06) were independent predictors of in-hospital mortality.

Conclusions: We found multiple predictors to be independently associated with in-hospital mortality, except diabetes and gender. Compared to reports from other countries, the in-hospital mortality among COVID-19 patients was lower, despite a high burden of co-morbidities. Further research is required to explore reasons behind this dichotomy.

Key words: COVID-19; Mortality; Pakistan; low-middle income country.

J Infect Dev Ctries 2021; 15(4):480-489. doi:10.3855/jidc.14345

(Received 11 November 2020 – Accepted 18 January 2021)

Copyright © 2021 Nasir et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Rapidly evolving data on COVID-19 from across the globe show that its disease severity and mortality are heterogeneous. The proportion of severely ill patients presenting to the hospital and in-hospital mortality of COVID-19 has been invariably high. Initial reports from the United Kingdom showed an in-hospital mortality was 26% in the 17% of patients admitted with severe to critical disease [1]. Similarly in the United States up to 25% of hospitalized patients were critically ill and the in-hospital mortality ranged from 21% to 25% [2,3]. These cases cannot be imputed or used as a surrogate for low middle-income countries due to the inherent differences in population health care access, immunity and, high background burden of communicable and non-communicable diseases. Data on hospitalized patients from developing countries are now being reported from tertiary care centers in the region. A study from Bangladesh has reported a 28-day mortality of 2.5% with a greater risk of death among elderly with co-morbid conditions [4]. Studies from India have shown that up to 14% of symptomatic patients developed a severe illness and the in-hospital mortality ranged was 4.5 to 5% with similar risk factors as those reported from Bangladesh [5,6]. A Single-center study from Egypt reported a greater incidence of hospitalization and severity in patients with an age of greater than 50 years [7]. Limited data have been reported from small studies in Pakistan largely confined to intensive care settings [8,9]. An elaborate understanding of clinical characteristics and outcomes of hospitalized COVID-19 patients in low-middle income countries (LMICs) represents an important knowledge gap given the heterogeneity of data from these countries [10]. Bridging this knowledge gap is necessary for increasing our understanding of the risks
and designing interventions for managing the most susceptible patients. To address this gap we evaluated clinical, biochemical, and radiological features and outcomes of COVID-19 in a larger cohort of 445 patients at an academic medical center in Karachi with a dedicated facility for COVID-19.

**Methodology**

**Study population and Design**

We conducted an observational study of adult COVID-19 patients hospitalized at the dedicated COVID-19 facility at the Aga Khan University Hospital between February 26 and June 10, 2020. We included all adult patients (≥ 18 years old) who had a discharge diagnosis of COVID-19 and had a positive PCR for COVID-19 RNA.

**Data collection**

We first curated a list of all patients hospitalized with a discharge diagnosis and positive PCR test for COVID-19 through the Hospital information management system. A detailed chart review was then conducted to extract demographics, clinical characteristics, outcomes, and treatment details of confirmed COVID-19 patients including underlying co-morbidities, laboratory and radiological investigations, and complications during hospitalization using a structured proforma. Patients were stratified based on the severity of illness which was defined as follows: a) Asymptomatic/Mild Illness: Patients who are either symptom-free or symptomatic COVID-19 patients who do not have hypoxia; b) Moderate Illness: Patients with evidence of lower respiratory disease during clinical assessment or imaging and who have a saturation of oxygen (SpO2) ≥90% on room air; c) Severe/Critical Illness: Patients with any of the following: SpO2 < 90% on room air, PaO2/FiO2 < 300 mm Hg, respiratory frequency >30 breaths/min, or > 50% infiltrates on chest radiograph and/or any of complications including respiratory failure/ARDS, septic shock, and/or multiple organ dysfunction.

**Diagnosis of COVID-19**

All included patients underwent nasopharyngeal swabs which were processed for detection of SARS-CoV-2 virus by real-time reverse transcriptase polymerase chain reaction (RT-PCR) using the WHO protocol for the 2019-nCoV RT-PCR assay in March 2020. Specimens in May were tested using the Cobas® SARS-CoV-2 RT-PCR assay (Roche Diagnostics, Indianapolis, IN, USA). A radiological diagnosis of pneumonia was made by evaluation of infiltrates observed on chest radiographs and/or CT chest. A multidisciplinary team of doctors including infectious disease consultants, pulmonologists, and intensivists was involved in the identification of cases and their management.

**Statistical analysis**

Descriptive analysis was performed for demographic features with mean and standard deviation or median with interquartile range (IQR) reported for quantitative variables such as age and lengths of hospital stay as appropriate. Frequencies (percentage) for qualitative variables such as gender, co-morbid conditions, mortality, and complications. Continuous variables were also transformed into categorical variables for further analysis as indicated. χ2 test of independence or Fischer exact test was performed for categorical variables such as comparison of those with COVID-19 who died with those who were discharged. We created univariable and multivariable logistic regression models to understand the association of risk factors associated with illness severity of COVID-19, (mild, moderate, and severe/critical). To identify factors independently associated with death in COVID-19 infection we created a stepwise multivariable logistic regression model. The model included variables found to be significant on univariable analysis and those deemed of clinical relevance. Unadjusted and adjusted odds ratios were reported. We included interaction terms to understand the interaction between age and gender. Significance was set at a value ≤0.05. STATA Version 12.1 was used for data analysis.

**Ethics approval**

This study received approval from the Aga Khan University Ethics Review Committee of the hospital (ERC reference number: 2020-3650-11773). The data was collected from hospital records and the requirement for informed consent was waived by the hospital ethical review committee as data was anonymized and no personal identifiers were collected.

**Results**

**Demographics, Clinical characteristics, and course of the disease**

Of a total of 11,393 adult patients admitted to the Aga Khan University Hospital between Feb 26, 2020, and June 10, 2020, 445 (3.9%) patients were diagnosed with COVID-19 based on RT-PCR positivity for SARS-CoV-2. Most of the hospitalized COVID-19 patients were male (298, 67%). The median age of the cohort was 53 years (IQR 40 – 64 years). Age was
further categorized into groups: 11.7% (N = 52) of the patients were between 18 and 29 years of age, 12.8% (N = 57) between 30 and 39 years, 18.4% (N = 84) between 40 and 49 years, 23.1% (N = 103) between 50 and 59 years, 18.8% (N = 84) between 60 and 69 years, 11.5% (N = 51) between 70 and 79 years, and 3.6% (N = 16) of the patients were greater than 80 years of age.

A total of 55 patients were (12.4%) asymptomatic and 137 (30.8%) had severe/critical disease. Most (268; 60.2%) patients had at least one or more than one co-morbidity, of which hypertension was the most common (37.5%) followed by diabetes (36.4%). Among symptomatic patients (n= 390, 87.6%), the most common symptom was fever (80%) followed by cough (61.3%) and shortness of breath (61.0%). The median duration of illness prior to presentation was 7 days (IQR 3-10) and was longer with worsening severity of illness (median of 3 days in mild, 7 days in moderate and severe each). Admissions peaked in May and then steadily reduced over time. The proportion of patients with severe disease increased with time; in March, 25% of admitted patients were severely ill and in May 34% of admitted patients had severe disease. Despite the increasing severity, the proportion of in-hospital mortality increased in May and started to decline in June (Figure 1). The median C-reactive protein (CRP) level was 83.3 mg/L (IQR: 27.8 -178.9) and the median ferritin level was 551 ng/ml (IQR: 254.1-1258.3). Overall, 124 (27.9%) required non-invasive ventilation (NIV) and 64 (14.5%) required invasive positive pressure (IPPV) ventilation. Chest X-rays were performed in 432 patients (97%). Chest X-rays were normal in 21.57% of patients. Unilateral involvement was seen less frequently as compared to bilateral disease (7.7% vs 66% respectively). Treatment received varied as the protocols changed with chloroquine use dropping from 2.25% of patients to zero between February and April. Similarly, hydroxychloroquine was given to 31% of patients overall with use declining from 47% to 2.1% between April and June. Among antivirals; nine patients received oseltamivir and two patients received lopinavir/ritonavir. Systemic steroids and intravenous tocilizumab were administered to moderate to severely ill patients with hypoxia and laboratory evidence of hyperinflammation. Overall, 56% of the patients (N=249) received systemic steroids and 19.3% (N=86) received intravenous tocilizumab during hospitalization. Sixty-eight patients (15%) required ICU admission. Septic shock was seen in 62 (14%) of the cases while 44 (9.9%) presented in multi-organ dysfunction. Acute kidney injury was seen in 96 (21.6%) and 46 (10.3%) patients presented with a

**Table 1.** Comparison of mild, moderate and severe COVID-19 patients admitted at tertiary care center in Karachi, Pakistan.

| Variables                        | All (N = 445) | Mild (N = 156) | Moderate (N = 152) | Severe (N = 137) | p-value |
|----------------------------------|---------------|---------------|--------------------|------------------|---------|
| Age* (mean ± SD)                 | 51.6 ± 16.1   | 42.3 ± 16.2   | 54.0 ± 12.7        | 59.4 ± 14.1      | < 0.001 |
| Gender*                          |               |               |                    |                  |         |
| Male                             | 298 (67%)     | 86 (55.1%)    | 108 (71.1%)        | 105 (76.6%)      | < 0.001 |
| Female                           | 147 (33%)     | 70 (44.9%)    | 44 (28.9%)         | 32 (23.4%)       |         |
| Duration of illness* [median (IQR) days] | 7 (3-10)    | 3 (0-7)       | 7 (5-10)           | 7 (5-10)         | < 0.001 |
| Co-morbides                      |               |               |                    |                  |         |
| Diabetes*                        | 162 (36.4%)   | 28 (17.9%)    | 70 (46.1%)         | 64 (46.7%)       | < 0.001 |
| Hypertension*                    | 167 (37.5%)   | 30 (19.2%)    | 65 (42.8%)         | 72 (52.6%)       | < 0.001 |
| Ischemic heart disease*          | 74 (16.6%)    | 10 (6.4%)     | 25 (16.4%)         | 39 (28.5%)       | < 0.001 |
| Chronic kidney disease*          | 31 (7%)       | 2 (1.3%)      | 13 (8.6%)          | 16 (11.7%)       | 0.001   |
| Malignancy                       | 22 (4.9%)     | 8 (5.1%)      | 5 (3.3%)           | 9 (6.6%)         | 0.601   |
| Stroke*                          | 10 (2.2%)     | 0 (0%)        | 3 (2%)             | 7 (5.1%)         | 0.007   |
| Chronic liver disease            | 8 (1.8%)      | 4 (2.6%)      | 1 (0.7%)           | 3 (2.2%)         | 0.739   |
Table 1 (continued). Comparison of mild, moderate and severe COVID-19 patients admitted at tertiary care center in Karachi, Pakistan.

| Variables                        | All (N = 445) | Mild (N = 156) | Moderate (N = 152) | Severe (N = 137) | p-value |
|----------------------------------|---------------|----------------|--------------------|------------------|---------|
| Symptoms                         |               |                |                    |                  |         |
| Fever*                           | 312 (70.1%)   | 83 (53.2%)     | 126 (82.9%)        | 103 (75.2%)      | < 0.001 |
| Cough*                           | 239 (53.7%)   | 56 (35.9%)     | 103 (67.8%)        | 80 (58.4%)       | < 0.001 |
| Shortness of breath*             | 238 (53.5%)   | 24 (15.4%)     | 100 (65.8%)        | 114 (83.2%)      | < 0.001 |
| Sore throat*                     | 48 (10.8%)    | 22 (14.1%)     | 18 (11.8%)         | 8 (5.8%)         | 0.028   |
| Myalgias                         | 52 (11.7%)    | 21 (13.5%)     | 16 (10.5%)         | 15 (10.9%)       | 0.736   |
| **Radiologic findings**         |               |                |                    |                  |         |
| Normal*                          | 96 (21.6%)    | 93 (59.6%)     | 3 (2%)             | 1 (0.7%)         | > 0.001 |
| Bilateral involvement*           | 291 (65.4%)   | 32 (20.5%)     | 133 (87.5%)        | 126 (92%)        | < 0.001 |
| Unilateral involvement           | 34 (7.6%)     | 10 (6.4%)      | 17 (11.2%)         | 7 (5.1%)         | 0.733   |
| Patchy infiltrates*              | 293 (65.8%)   | 33 (21.2%)     | 137 (90.1%)        | 123 (89.8%)      | < 0.001 |
| Multilobar involvement*          | 178 (40%)     | 14 (9%)        | 85 (55.9%)         | 79 (57.7%)       | < 0.001 |
| Consolidation*                   | 48 (10.8%)    | 7 (4.5%)       | 18 (11.8%)         | 23 (16.8%)       | 0.001   |
| CURB score* [median (IQR)]       | 1 (0-2)       | 0 (0)          | 1 (0-1)            | 2 (1-3)          | < 0.001 |
| **Laboratory Investigations**    |               |                |                    |                  |         |
| C- Reactive Protein* < 150 mg/L  | 252 (56.6%)   | 96 (61.5%)     | 105 (69.1%)        | 51 (37.2%)       | < 0.001 |
| C- Reactive Protein >= 150 mg/L | 193 (43.4%)   | 60 (38.5%)     | 47 (30.9%)         | 86 (62.8%)       | < 0.001 |
| LDH* < 500 IU/L                  | 235 (52.8%)   | 81 (51.9%)     | 109 (71.7%)        | 45 (32.8%)       | 0.003   |
| LDH* > 500 IU/L                  | 210 (47.2%)   | 75 (48.1%)     | 43 (28.3%)         | 92 (67.2%)       | < 0.001 |
| Neutrophil to lymphocyte ratio*  | 255 (57.3%)   | 118 (75.6%)    | 95 (62.5%)         | 42 (30.7%)       | < 0.001 |
| Neutrophil to lymphocyte ratio*  | 190 (42.7%)   | 38 (24.4%)     | 57 (37.5%)         | 95 (69.3%)       | < 0.001 |
| Ferritin < 1500 ng/ml            | 249 (56%)     | 84 (53.8%)     | 104 (68.4%)        | 61 (44.5%)       | 0.162   |
| Ferritin > = 1500 ng/ml          | 196 (44%)     | 72 (46.2%)     | 48 (31.6%)         | 76 (55.5%)       | < 0.001 |
| **Type of Ward**                 |               |                |                    |                  |         |
| ICU Admission*                   | 68 (15.3%)    | 0 (0%)         | 1 (0.7%)           | 67 (48.9%)       | < 0.001 |
| SCU Admission*                   | 148 (33.3%)   | 12 (7.7%)      | 75 (49.3%)         | 61 (44.5%)       | < 0.001 |
| Ward admission*                  | 223 (50.1%)   | 141 (90.4%)    | 76 (50%)           | 6 (4.4%)         | < 0.001 |
| **Treatment**                    |               |                |                    |                  |         |
| Non-invasive ventilation*        | 124 (27.9%)   | 0 (0%)         | 35 (23%)           | 89 (65%)         | < 0.001 |
| Invasive ventilation*            | 64 (14.4%)    | 0 (0%)         | 0 (0%)             | 64 (46.7%)       | < 0.001 |
| Oxygen support*                  | 278 (62.5%)   | 8 (5.1%)       | 135 (88.8%)        | 135 (98.5%)      | < 0.001 |
| Antibiotics*                     | 236 (53%)     | 25 (16%)       | 86 (56.6%)         | 125 (91.2%)      | < 0.001 |
| Azithromycin*                    | 164 (36.9%)   | 16 (10.3%)     | 68 (44.7%)         | 80 (58.4%)       | < 0.001 |
| Hydroxychloroquine*              | 139 (31.2%)   | 11 (7.1%)      | 67 (44.1%)         | 61 (44.5%)       | < 0.001 |
| Chloroquine                      | 10 (2.2%)     | 1 (0.6%)       | 4 (2.6%)           | 5 (3.6%)         | 0.093   |
| Tocilizumab*                     | 86 (19.3%)    | 0 (0%)         | 21 (13.8%)         | 64 (46.7%)       | < 0.001 |
| Oseltamivir*                     | 9 (2%)        | 0 (0%)         | 3 (2%)             | 6 (4.4%)         | 0.014   |
| Lopinavir/Ritonavir              | 3 (0.7%)      | 0 (0%)         | 1 (0.7%)           | 2 (1.5%)         | 0.161   |
| Systemic steroids*               | 249 (56%)     | 6 (3.8%)       | 120 (78.9%)        | 123 (89.8%)      | < 0.001 |
| Vasopressors*                    | 59 (13.3%)    | 0 (0%)         | 1 (0.7%)           | 58 (42.3%)       | < 0.001 |
| **Complications**                |               |                |                    |                  |         |
| ARDS*                            | 122 (27.4%)   | 0 (0%)         | 19 (12.5%)         | 103 (75.2%)      | < 0.001 |
| Septic Shock*                    | 62 (13.9%)    | 0 (0%)         | 0 (0%)             | 62 (45.3%)       | < 0.001 |
| MODS*                            | 44 (9.9%)     | 0 (0%)         | 3 (2%)             | 41 (29.9%)       | < 0.001 |
| Nosocomial Infection*            | 59 (13.3%)    | 1 (0.6%)       | 10 (6.6%)          | 48 (35%)         | < 0.001 |
| AKI*                             | 96 (21.6%)    | 5 (3.2%)       | 21 (13.8%)         | 70 (51.1%)       | < 0.001 |
| NSTEMI*                          | 46 (10.3%)    | 1 (0.6%)       | 9 (5.9%)           | 36 (26.3%)       | < 0.001 |
| Length of stay* [median (IQR) days] | 5 (3-9)     | 3 (2-5)        | 6 (4-9)            | 8 (5-14)         | < 0.001 |
| Dead*                            | 58 (13%)      | 0 (0%)         | 3 (2%)             | 55 (40.1%)       | < 0.001 |
| Discharged*                      | 360 (80.9%)   | 144 (92.3%)    | 142 (93.4%)        | 74 (54%)         | < 0.001 |
| Left against medical advice (LAMA) | 27 (6.1%)   | 12 (7.7%)      | 7 (4.6%)           | 8 (5.8%)         |         |

* significant at p-value < 0.05; i: These were patients with severe disease admitted for comfort care; ii: This includes patient who had polytrauma, hematemesis, gastrointestinal bleed etc. who were incidentally diagnosed with COVID-19; iii: These were varied, one with underlying malignancy, one with penumoperitoneum who was found on preop screening, a couple had raised ferritin only.
ICU mortality was 58.8% (40/68). A total of 58 patients died with an overall mortality rate of 13%. (Table 1).

**Comparison of Severe, moderate, and mild disease**

In all, 35% of patients had asymptomatic/mild disease, 34% moderate, and 30% had severe/critical disease on admission. Compared with patients with asymptomatic/mild and moderate disease, patients with severe disease were older, (severe disease: mean 59 years vs mild disease 42 years); and were likely to have co-morbidities such as diabetes, hypertension, and ischemic heart disease ($p$-value < 0.001).

A greater proportion of patients with severe disease had shortness of breath (83%) on presentation. Chest radiographic with bilateral peripheral opacities were seen in majority of the patients with moderate (87.5%) and severe disease (92%) whereas most of the mildly diseased patients (60%) had a normal chest x-ray. Patients with greater severity of illness had significantly higher median CRP, ferritin, LDH, and D-Dimer values as well as a higher mean neutrophil to lymphocyte ratio compared to those with mild and moderate disease ($p$-value < 0.001). Hydroxychloroquine was given to 44% patients with moderate and 44% patients with severe disease respectively. Intravenous steroids were used in majority of the patients with moderate and severe disease (79% and 90% respectively). Intravenous Tocilizumab was administered to 86 (19.3%) cases and predominantly among those with severe disease (47.4%). Antibiotic use was common in severe disease with 91% receiving any antibiotics as opposed to 16.5% of the mild and 57% of moderate cases.

**Associations of Severity of Illness**

Ordinal logistic regression was performed to determine predictors of severity (Table 2). Multivariable ordinal regression analysis revealed that the risk of having severe disease was 1.92 (95% CI: 1.23 - 3.03) times higher in patients with age ≥ 60 years when compared with patients < 60 years. Presence of shortness of breath at presentation (OR = 4.43; 95% CI: 2.73-7.22) and presence of bilateral peripheral opacities on chest radiograph was associated with greater severity of illness (OR=5.81; 95% CI: 2.90-11.62). Among laboratory investigations done on admission; the risk of greater severity of illness was associated with CRP ≥ to 150mg/L (OR=1.77; 95% CI: 1.10-2.85), LDH ≥ 500 I.U/L (OR=1.98; 95% CI: 1.25-3.16), Neutrophil to Lymphocyte ratio ≥ 5 (OR = 2.80; 95% CI: 1.77-4.42) and a unit increase in serum creatinine level in mg/dl (OR=1.32; 95% CI: 1.07-1.61). None of the treatment modalities had any statistically significant impact on the severity of illness.

**Factors associated with odds of death**

Univariable predictors of death included older age, male sex, co-morbid conditions, and presence of complications such as septic shock, multi-organ dysfunction, acute kidney injury, myocardial infarction, and nosocomial infections (Table 3). Majority of the patients who died (69%) had been admitted to the ICU. There was only one death in the ward due to an underlying malignancy. All of the 17 patients who died in the High Dependency Units had a code status of was either Do-Not-Resuscitate (DNR) or comfort care due to an underlying terminal illness.

**Table 2. Multivariable ordinal logistic regression for factors associated with level of severity.**

| Variable                          | Categories    | OR       | 95% CI  | p-value |
|-----------------------------------|---------------|----------|---------|---------|
| Age                               | < 60 years (Ref) | 1        |         |         |
|                                   | ≥ 60 years    | 1.93     | 1.23-3.03 | 0.004   |
| Shortness of breath               | Absent (Ref)  | 1        |         |         |
|                                   | Present       | 4.44     | 2.73-7.22 | < 0.001 |
| Bilateral chest radiographic finds | Absent (Ref)  | 1        |         |         |
|                                   | Present       | 3.13     | 1.58-6.17 | 0.001   |
| Patchy infiltrates                | Absent (Ref)  | 1        |         |         |
|                                   | Present       | 5.81     | 2.90-11.6 | < 0.001 |
| C-Reactive Protein                | < 150 (Ref)   | 1        |         |         |
|                                   | ≥ 150         | 1.77     | 1.09-2.85 | 0.019   |
| Lactate dehydrogenase             | < 500(Ref)    | 1        |         |         |
|                                   | ≥ 500         | 1.98     | 1.25-3.16 | 0.004   |
| Neutrophil to lymphocyte ratio    | < 5 (Ref)     | 1        |         |         |
|                                   | ≥ 5           | 2.80     | 1.77-4.42 | < 0.001 |
| Creatinine* on admission          |               | 1.32     | 1.07-1.61 | 0.008   |

*per unit increase.
Table 3. Risk Factors associated with mortality.

| Variables                               | Died (N = 58) | Recovered (N = 360) | Univariable OR (95% CI) | p-value | Multivariable OR (95% CI) | p-value |
|-----------------------------------------|---------------|---------------------|-------------------------|---------|--------------------------|---------|
| Age groups**                            |               |                     |                         |         |                          |         |
| < 60 years (Ref)                        | 23            | 257                 | 1                       |         | 3.26 (1.07-9.89)         | 0.037   |
| >= 60 years                             | 35            | 103                 | 3.79 (2.14-6.74)        | < 0.001 | 3.26 (1.07-9.89)         | 0.037   |
| Gender*                                 |               |                     |                         |         |                          |         |
| Female (Ref)                            | 11            | 130                 | 1                       |         |                          |         |
| Male                                    | 47            | 230                 | 2.42 (1.21-4.82)        | 0.012   |                          |         |
| Co-morbid (present vs. not present)     |               |                     |                         |         |                          |         |
| Diabetes**                              | 28            | 124                 | 1.78 (1.02-3.11)        | 0.044   |                          |         |
| Hypertension**                          | 31            | 124                 | 2.18 (1.25-3.83)        | 0.006   |                          |         |
| Ischemic heart disease**                | 20            | 50                  | 3.26 (1.76-6.06)        | < 0.001 | 3.26 (1.07-9.89)         | 0.037   |
| CKD*                                    | 12            | 17                  | 5.26 (2.36-11.72)       | < 0.001 |                          |         |
| Malignancy*                             | 7             | 12                  | 3.98 (1.50-10.58)       | 0.006   |                          |         |
| Radiologic findings (present vs. absent)|               |                     |                         |         |                          |         |
| Bilateral patchy infiltrates*           | 52            | 224                 | 5.14 (2.15-12.30)       | < 0.001 |                          |         |
| Laboratory investigations               |               |                     |                         |         |                          |         |
| NLR**                                   |               |                     |                         |         |                          |         |
| < 5 (ref)                               | 15            | 227                 | 1                       |         | 4.04 (1.14-14.35)        | 0.031   |
| >= 5                                    | 43            | 133                 | 4.89 (2.62-9.14)        | < 0.001 |                          |         |
| Ferritin**                              |               |                     |                         |         |                          |         |
| < 1500                                  | 18            | 217                 | 1                       |         |                          |         |
| >= 1500                                 | 40            | 143                 | 3.37 (1.86-6.11)        | < 0.001 | 3.78 (1.21-11.8)         | 0.022   |
| CRP**                                   |               |                     |                         |         |                          |         |
| < 150 (ref)                             | 23            | 216                 |                         |         |                          |         |
| >= 150                                  | 35            | 144                 | 2.28 (1.29-4.02)        | 0.004   |                          |         |
| D-Dimer*                                |               |                     |                         |         |                          |         |
| < 1.5 (Ref)                             | 14            | 206                 |                         |         |                          |         |
| >= 1.5                                  | 44            | 154                 | 4.20 (2.22-7.94)        | < 0.001 |                          |         |
| Creatinine*                             |               |                     |                         |         |                          |         |
| < = 1.2 (Ref)                           | 19            | 264                 |                         |         |                          |         |
| > 1.2                                   | 39            | 96                  | 5.64 (3.11-10.24)       | < 0.001 |                          |         |
| Type of admission unit                  |               |                     |                         |         |                          |         |
| ICU **                                  | 40            | 22                  | 34.14 (16.9-69)         | < 0.001 | 3.99 (1.22-13)           | 0.022   |
| SCU                                      | 17            | 123                 | 0.78 (0.43-1.46)        | 0.468   |                          |         |
| Ward*                                   | 1             | 211                 | 0.012 (0.001-0.09)      | < 0.001 |                          |         |
| Treatment                               |               |                     |                         |         |                          |         |
| NIV*                                    | 34            | 83                  | 4.72 (2.65-8.42)        | < 0.001 |                          |         |
| Invasive ventilation*                   | 36            | 22                  | 25.14 (12.69-49.80)     | < 0.001 |                          |         |
| Oxygen support*                         | 57            | 204                 | 43.5 (5.97-318.24)      | < 0.001 |                          |         |
| Systemic steroids*                      | 50            | 187                 | 5.78 (2.67-12.54)       | < 0.001 |                          |         |
| Tocilizumab*                            | 19            | 66                  | 2.21 (1.20-4.07)        | 0.01    |                          |         |
| Complications present (vs absent)       |               |                     |                         |         |                          |         |
| ARDS*                                   | 51            | 62                  | 35.01 (15.1-80.8)       | < 0.001 |                          |         |
| Septic Shock**                          | 46            | 10                  | 134 (54.89-327.9)       | < 0.001 | 13.27 (3.78-46.65)       | < 0.001 |
| MODS**                                  | 34            | 6                   | 83.5 (31.96-218.58)     | < 0.001 | 8.60 (2.08-35.64)        | 0.003   |
| Nosocomial Infection*                   | 29            | 27                  | 12.33 (6.46-23.55)      | < 0.001 |                          |         |
| AKI**                                   | 47            | 43                  | 31.39 (15.13-65.13)     | < 0.001 | 5.52 (1.78-17.06)        | 0.003   |
| NSTEMI*                                 | 21            | 21                  | 9.16 (4.58-18.33)       | < 0.001 |                          |         |
| Median Length of stay in days* (IQR)    | 8 (3-14)      | 5 (3-9)             | 1.04 (1.01-1.07)        | 0.016   |                          |         |

* significant on univariable analysis at p-value<0.05; ** significant on multivariable analysis at p-value<0.05. CKD: Chronic kidney disease; CXR: Chest X-ray; NLR: neutrophil to lymphocyte ratio; CRP: C-reactive protein; ICU: Intensive care unit; SCU: Special care unit; NIV: Non-invasive ventilation; ARDS: Acute respiratory distress syndrome; MODS: Multi-organ dysfunction Syndrome; AKI: Acute kidney injury; NSTEMI: Non-ST elevation myocardial infarction.
Presence of septic shock (AOR = 13.2; 95%CI: 3.78-46.65), multi-organ dysfunction (AOR= 8.6 (95%CI: 2.08- 35.64), acute kidney injury (AOR= 5.52; 95%CI: 1.78-17.06), admission to the ICU (AOR = 3.99; 1.78- 2.08- 35.64), acute kidney injury (AOR= 5.52; 95%CI: 46.65), multi-organ dysfunction (AOR= 8.6 (95%CI: 1.07 – 9.89) serum ferritin ≥ 1500ng/ml (AOR= 3.78; 95%CI: 1.21 -11.8) and NLR ≥ 5 (AOR = 4.04; 95%CI:1.14-14.35) were independently associated with mortality. None of the treatment options were found to have any significant benefit on mortality or length of stay. We tested for interactions between age, sex, and diabetes but these were not significant.

Discussion

Our study highlights some of the differences in outcomes and severity seen in LMIC compared to previously reported studies. While our overall inpatient mortality was 13% and the patients had a significant burden of comorbid conditions, some of the “classic” risk factors for mortality were not found. While comorbid conditions were associated with mortality on univariable analysis, these were not found to be independent predictors of death on multivariable analysis. This is in contrast to most studies, which report an independent association of mortality with comorbid conditions such as diabetes, chronic kidney disease, and malignancy [11–15]. This is quite interesting considering the greater proportion of our cohort were diabetics (36% compared to 7.5 to 19% in China and 13 % in Italy). Few studies report a similar absence of statistically significant association between comorbid conditions and severity[16, 17]. Possibly, the baseline control of comorbid conditions may have influenced outcomes. For instance, uncontrolled inpatient hyperglycemia, with or without known diabetes, is an independent predictor of worse outcomes [18–20]. Data on baseline and inpatient control of comorbid conditions was not collected in our study. Future analyses of the association of outcomes with comorbid conditions should be stratified according to comorbid control to better describe the possible relationship. In our study, in-hospital mortality was 13.88%, and the mean length of hospitalization was 7.37 days. In-hospital mortality has been reported to be 28% from tertiary care centers in China [21], 21.7% from centers in New York [13], 20% from Iran [22], and 35% in-hospital mortality from a single center study in Italy [23]. Our ICU mortality was 58.8% which is comparable to the estimated case fatality rate ranging from 40% to 59% of ICU admissions who require invasive mechanical ventilation [24–26]. However, there has been wide variability in data reported from different parts of the world. ICU mortality was reported as 26 % from large multicenter case series from Lombardy, Italy [27], 35.8% from a National cohort study from the UK [28], 31% in a multicenter study from Spain [29], 53% from a large center in New York, USA [30], and 56% from a tertiary care center in India [31]. The heterogeneity in these figures is explained by limited ICU resources particularly in pandemic epicenters and may have been influenced by the age of the affected population [24]. Our ICU mortality rate parallels that which is reported from large centers in both US and India. To better characterize differences in mortality, we determined the risk factors for death among hospitalized patients. Our study showed that multi-organ dysfunction, septic shock, and admission to the intensive care unit on presentation were associated with mortality. These are similar to risk factors reported from other regions across the globe, though individual risk factors have varied [13,32]. Similarly, acute kidney injury was also an independent predictor of mortality as has been reported from various countries as well [32]. Second, on multivariate analysis of laboratory parameters at presentation, only the NLR was found to have a statistically significant association with both disease severity and mortality. CRP, LDH, and creatinine were found to be associated with disease severity alone, whereas ferritin was associated with mortality alone. Associations between higher levels of biochemical and hematological markers of inflammation and organ dysfunction with increasing disease severity and mortality was also observed, consistent with literature from other centers [33]. However, our study supports the early use of NLR as a single marker for risk stratification for both disease progression and mortality, making this cost-effective and readily available tool especially valuable in resource-limited settings. Similar to other studies [34–37], we also found age to be a risk factor for severe disease. A possible explanation for this may be the impaired immune responses with advancing age as both innate and cell-mediated immune mechanisms decline to cause unchecked viral replication and exaggerated proinflammatory immune mechanisms decline to cause unchecked viral replication and exaggerated proinflammatory immune mechanisms decline to cause unchecked viral replication and exaggerated proinflammatory immune mechanisms decline to cause unchecked viral replication and exaggerated proinflammatory immune mechanisms decline to cause unchecked viral replication and exaggerated proinflammatory immune mechanisms decline to cause unchecked viral replication and exaggerated proinflammatory immune mechanisms...
We found a greater incidence of nosocomial infections compared to other studies [41–43]. Nosocomial infections were also associated with mortality in univariable analysis, which may be related to immunosuppression with tocilizumab and steroids. This may be an important observation in the context of low-middle income countries where the incidence of nosocomial infections is higher and can contribute to poor outcomes [44] in COVID-19. Our study highlights important differences in factors associated with severity and mortality particularly relevant to a low-middle income country whereby despite a high prevalence of diabetes and increased incidence of nosocomial infections there was comparatively lower in-hospital mortality. One of the reasons for this could be that 66% of the patients were less than 60 years of age and therefore as opposed to developed countries, a relatively younger age group was affected. This may also explain the case fatality rate from Pakistan which has remained around 2-3% which is considerably lower than Italy and Iran but similar to CFR reported from China and India [45]. There has been considerable speculation on the reasons behind this phenomenon and it has been postulated that both genetic and environmental factors may have a role despite the resource constraints [10]. However, some limitations need to be recognized that may limit generalizability. These include retrospective data collection, single-center nature of the study. Moreover, the varying treatment protocols, as more data became available, influenced clinical practices, and may have had bearing on the results of the study. Notwithstanding limitations, the present study emphasizes the key epidemiological differences in the nature of the outbreak experienced in Pakistan which need to be explored and validated in other similarly situated LMICs and population studies.

Acknowledgements
Dr. Tashfeen Ahmad (Assistant Professor, Department of Surgery, Aga Khan University, Karachi, Pakistan) contributed to the data analysis and graphical presentation.

References
1. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Ho A, Russell CD, Dunning J, Openshaw PJ, Bailie JK, Semple MG (2020) Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 369: m1985.
2. Bahl A, Van Baalen MN, Ortiz L, Chen N-W, Todd C, Milad M, Yang A, Tang J, Nygren M, Qu L (2020) Early predictors of in-hospital mortality in patients with COVID-19 in a large American cohort. Intern Emerg Med 1:1485-1499.
3. Horwitz LI, Jones SA, Cerfolio RJ, Francois F, Greco J, Rudy B, Petrilli CM (2020) Trends in COVID-19 Risk-Adjusted Mortality Rates. J Hosp Med 16: 90-92.
4. Islam MZ, Riaz BK, Islam ANMS, Khanam F, Akhter J, Choudhury R, Farhana N, Jahan NA, Uddin MJ, Efa SS (2020) Risk factors associated with morbidity and mortality outcomes of COVID-19 patients on the 28th day of the disease course: a retrospective cohort study in Bangladesh. Epidemiol Infect 148: e263. doi: 10.1017/S0950268820002630.
5. Jain AC, Kansal S, Sardana R, Bahl RK, Kar S, Chawla R (2020) A Retrospective Observational Study to Determine the Early Predictors of In-hospital Mortality at Admission with COVID-19. Indian J Crit Care Med 24: 1174–1179.
6. Saurabh S, Verma MK, Gautam V, Kumar N, Jain V, Goel AD, Gupta MK, Sharma PP, Bhardwaj P, Singh K, Nag VL, Garg MK, Misra S (2021) Tobacco, alcohol use and other risk factors for developing symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: a case–control study from western Rajasthan, India. Trans R Soc Trop Med Hyg: 10.1093/trstmh/traa172. doi: 10.1093/trstmh/traa172. Online ahead of print.
7. Kassas ME, Asem N, Abdelazeem A, Madkour A, Sayed H, Tawheed A, Shaffie AA, Gamal M, Elsayed H, Badr M, Hassany M, Omran D, Fouly AE (2020) Clinical features and laboratory characteristics of patients hospitalized with COVID-19: single centre report from Egypt. J Infect Dev Ctries 14: 1352–1360. doi: 10.3855/jidc.13156.
8. Asghar MS, Haider Kazmi SJ, Ahmed Khan N, Akram M, Ahmed Khan S, Rasheed U, Hassan M, Memon GM (2020) Clinical Profiles, Characteristics, and Outcomes of the First 100 Admitted COVID-19 Patients in Pakistan: A Single-Center Retrospective Study in a Tertiary Care Hospital of Karachi. Cureus 12: e8712.
9. Rahim F, Amin S, Noor M, Bahadur S, Gul H, Mahmood A, Usman M, Khan MA, Ullah R, Shahab K (2020) Mortality of Patients With Severe COVID-19 in the Intensive Care Unit: An Observational Study From a Major COVID-19 Receiving Hospital. Cureus 12: e10906.
10. Gupta R, Misra A (2020) COVID19 in South Asians/Asian Indians: Heterogeneity of data and implications for pathophysiology and research. Diabetes Res Clin Pract 165:108267.
11. Moccia F, Gerbino A, Lionetti V, Miragoli M, Munaron LM, Pagliaro P, Pasqua T, Penna C, Rocca C, Samaja M, Angelone T (2020) COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. Geroscience 42: 1021-1049.
12. Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, Wang Y (2020) Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis 99: 47–56.
13. Mikami T, Miyashita H, Yamada T, Harrington M, Steinberg D, Dunn A, Siau E (2020) Risk Factors for Mortality in Patients with COVID-19 in New York City. J Gen Intern Med 36: 17-46.

14. Albittar O, Ballouze R, Ooi JP, Sheikh Ghadzi SM (2020) Risk factors for mortality among COVID-19 patients. Diabetes Res Clin Pract 166: 108293.

15. Parohan M, Yaghoobi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M (2020) Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male 1-9.

16. Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, Liu W, Tu C, Zhu M, Xiong B (2020) COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res 43: 824-831.

17. Saleyni G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, Demertzis Z, Hanna Z, Failla A, Dagher C, Chaudhry Z, Vahia A, Abreu Lanfranco O, Ramesh M, Zervas MJ, Alangaden G, Miller J, Bear J (2020) Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw Open 3: e2012270.

18. Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, Klonoff DC (2020) Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol 14: 813–821.

19. Wu J, Huang J, Zhu G, Wang Q, Lv Q, Huang Y, Yu Y, Si X, Yi H, Wang C, Liu Y, Xiao H, Zhou Q, Liu X, Yang D, Guo X, Li Y, Peng S, Sung J, Xiao H (2020) Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study. BMJ Open Diabetes Res Care 8: e001476.

20. Zhu L, She Z-G, Cheng X, Qin J-J, Zhang X-J, Cai J, Lei F, Wang H, Xie J, Wang W, Li H, Zhang P, Song X, Chen X, Xiang M, Zhang C, Bai L, Xiang D, Chen M-M, Liu Y, Yan Y, Liu M, Mao W, Zou J, Liu L, Chen G, Luo P, Xiao B, Zhang C, Zhang Z, Lu Z, Wang J, Lu H, Xie X, Wang D, Liao X, Peng G, Ye P, Yang J, Yuan Y, Huang X, Guo J, Zhang B-H, Li H (2020) Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 31: 1068-1077.e3.

21. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl 395: 1054–1062.

22. Jalili M, Payandemehr P, Saghaei A, Sari HN, Safikhani H, Kolivand P (2020) Characteristics and Mortality of Hospitalized Patients With COVID-19 in Iran: A National Retrospective Cohort Study. Ann Intern Med 174: 125-127.

23. Sulejmani A, Galimberti E, Giacobone C, Milano A, Scopetta E, Intra J, Falbo R, Sarto C, Leoni V, Brambilla P (2021) Baseline characteristics of COVID-19 Italian patients admitted to Desio Hospital, Lombardy: a retrospective study. Scand J Clin Lab Invest 81: 18-23.

24. Lim ZJ, Subramaniam A, Ponnapa Reddy M, Blecher G, Kadam U, Afroz A, Billah B, Ashwin S, Kubicki M, Bilotta F, Curtis JR, Rubulotta F (2021) Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis. Am J Respir Crit Care Med 203: 54–66.

25. Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M (2020) Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care 24: 516.

26. Serafin RB, Póvoa P, Souza-Dantas V, Kalil AC, Sallah JIF (2021) Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review. Clin Microbiol Infect 27: 47–54.

27. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foci G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A, COVID-19 Lombardy ICU Network (2020) Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 323: 1574–1581.

28. Dennis JM, McGovern AP, Vollmer SJ, Mateen BA (2021) Improving Survival of Critical Care Patients With Coronavirus Disease 2019 in England: A National Cohort Study, March to June 2020. Crit Care Med 49: 209–214.

29. Ferrando C, Mellado-Artigas R, Gea A, Arruti E, Aldecoa C, Bordell A, Adalia R, Zattera L, Ramasco F, Monedero P, Maseda E, Martinez A, Tamayo G, Mercadal J, Muñoz G, Jacas A, Angeles G, Castro P, Hernández-Jejero M, Fernandez J, Gómez-Rojo M, Cardelà A, Ripollés J, Nieto A, Bessa E, Deiros C, Margarit A, Redondo FJ, Martín A, Garcia N, Casas P, Morcillo C, Hernández-Sanz ML, de la Red de UCI Española para COVID-19 (2020) Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: A prospective, cohort, multicentre study. Rev Esp Anestesiol Reanim 67: 425–437.

30. Filardo TD, Khan MR, Krawczyk N, Galitzer H, Karmen-Tuoky S, Coffee M, Schaye VE, Eckhardt BJ, Cohen GM (2020) Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020). PLOS ONE 15: e0242760.

31. Gupta N, Ish P, Kumar R, Dev N, Yadav SR, Malhotra N, Agrawal S, Gaind R, Sachdeva H, Covid Working Group OMOTISH (2020) Evaluation of the clinical profile, laboratory parameters and outcome of two hundred COVID-19 patients from a tertiary centre in India. Monaldi Arch Chest Dis Arch Monaldi Mal Torace 90.

32. Chen F, Sun W, Sun S, Li Z, Wang Z, Yu L (2020) Clinical characteristics and risk factors for mortality among inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. J Med Virol 93: 1078-1098.

33. Williamson EM, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HI, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas II, Rentsch CT, Mathur R, Wong AYS, Greive R, Harrison D, Forbes H, Schulzle A, Croker R, Parry J, Hester F, Harper S, Peera R, Evans JW, Smeth L, Goldacre B (2020) Factors associated with COVID-19-related death using OpenSAFELY. Nature 584: 430–436.

34. Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J, Arora S, Southern WN, Mantzoros CS (2020) Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-
hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 108: 154262.

36. Nikpouraghdam M, Jalalifarahani A, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, Sepandi M, Jafari NJ, Izadi M, Qazvini A, Dorostkar R, Tat M, Shahriari A, Farnoosh G, Hosseini Zijoud SR, Taghdir M, Alimohamady I, Abbaszadeh S, Gouvarchin Ghaleh HE, Bagheri M (2020) Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol 127: 104378.

37. Imam Z, Odish F, Gill I, O’Connor D, Armstrong J, Vanood A, Ibironke O, Hanna A, Ranski A, Halalau A (2020) Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med 288: 469–476.

38. Asfahan S, Deokar K, Dutt N, Niwas R, Jain P, Agarwal M (2020) Extrapolation of mortality in COVID-19: Exploring the role of age, sex, co-morbidities and health-care related occupation. Monaldi Arch Chest Dis Arch Monaldi Mal Torace 90.

39. Parra-Bracamonte GM, Lopez-Villalobos N, Parra-Bracamonte FE (2020) Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. Ann Epidemiol 52: 93-98.e2.

40. Bhopal SS, Bhopal R (2020) Sex differential in COVID-19 mortality varies markedly by age. Lancet Lond Engl 396: 532–533.

41. Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, Fernandez-Pittot M, Pitart C, Inciarte A, Bodro M, Morata L, Ambrosioni J, Grañia I, Meira F, Macaya I, Cardozo C, Casals C, Tellez A, Castro P, Marco F, Garcia F, Mensa J, Martinez JA, Soriano A, Rico V, Hernández-Meneses M, Agüero D, Torres B, González A, Mora L de la, Rojas J, Linares L, Fidalgo B, Rodriguez N, Nicolas D, Albiach L, Muñoz J, Almuedo A, Camprubí D, Marcos MA, Camprubí D, Cillóniz C, Fernández S, Nicolas JM, Torres A (2021) Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 27: 83–88.

42. Nori P, Cowman K, Chen V, Bartash R, Szymbczak W, Madaline T, Punjabi Kattyar C, Jain R, Aldrich M, Weston G, Gielanella P, Corpuz M, Gendlina I, Guo Y (2021) Bacterial and fungal co-infections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol 42: 84.88.

43. He Y, Li W, Wang Z, Chen H, Tian L, Liu D (2021) Nosocomial infection among patients with COVID-19: A retrospective data analysis of 918 cases from a single center in Wuhan, China. Infect Control Hosp Epidemiol 41: 982-983.

44. Allegranzi B, Nejad SB, Combes C, Graafmans W, Attar H, Donaldson L, Pittet D (2011) Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet 377: 228-241.

45. Government of Pakistan (2021) COVID-19 Dashboard. Available: https://covid.gov.pk/stats/pakistan. Accessed 17 January 2021.

Corresponding author
Corresponding author
Nosheen Nasir, FRCP, FCPS, MSc
Department of Medicine, Aga Khan University, Stadium Road, Karachi 74800, Pakistan, Phone: +923332133936
Fax: +922134932095
Email: nosheen.nasir@aku.edu

Conflict of interests: No conflict of interests is declared.